Caredx announces presentation of 60 abstracts including 19 oral presentations at the 2025 international society for heart and lung transplantation meeting

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that caredx, together with study collaborators from leading transplant centers, will present the latest advancements in clinical evidence supporting its transplant care solutions at the inter.
CDNA Ratings Summary
CDNA Quant Ranking